Spots Global Cancer Trial Database for AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
Official Title: An Open-label, Dose-escalation Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of AsiDNA, a DNA Repair Inhibitor Administered Intravenously, as Single Agent and to Assess the Safety and the Efficacy of AsiDNA in Combination With Carboplatin With or Without Paclitaxel, in Patients With Advanced Solid Tumors
Study ID: NCT03579628
Conditions
Interventions
Study Description
Brief Summary: The aim of the study is to assess: * Part A: the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AsiDNA in patients with advanced solid tumors. * Part B: the safety and preliminary efficacy of AsiDNA in combination with Carboplatin with or without Paclitaxel in patients with Advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institut Jules Bordet, Bruxelles, , Belgium
Grand Hôpital de Charleroi, Charleroi, , Belgium
Centre Leon Berard, Lyon, , France
Institut Curie, Paris, , France
Institut Claudius Regaud, Toulouse, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
